# Heparin

Drug · id `cardio:heparin` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Heparin sodium

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Heparin is an anticoagulant given by injection. The US label read, for Heparin Sodium Injection, lists these uses: prophylaxis and treatment of venous thrombosis and pulmonary embolism; prevention of postoperative deep venous thrombosis and pulmonary embolism in people having major abdominothoracic surgery or otherwise at risk; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies; prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism; and use as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures. The label says heparin does not dissolve existing clots.

## Technical summary

RxNorm ingredient 5224; UNII ZZ45AB24CA is the UNII of heparin sodium, the form the label names, and is a broad match. MeSH descriptor D006493 is Heparin. Class: Unfractionated Heparin (FDA established pharmacologic class, RxClass), which this atlas files under the class page for heparins and low-molecular-weight heparins. The label read is the Fresenius Kabi USA, LLC label for Heparin Sodium Injection, application NDA017029, effective 2026-04-30 in openFDA. Heparin is sold by several sponsors under several applications; other labels were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of heparin sodium injection lists an indication: venous thrombosis, pulmonary embolism, atrial fibrillation with embolization, consumptive coagulopathy, arterial and cardiac surgery, peripheral arterial embolism

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Heparin Sodium Injection, in the Fresenius Kabi USA, LLC version dated 2026-04-30 in openFDA, describes heparin as an anticoagulant and lists it for the prophylaxis and treatment of venous thrombosis and pulmonary embolism; the prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or otherwise at risk of thromboembolic disease; atrial fibrillation with embolization; the treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); the prevention of clotting in arterial and cardiac surgery; the prophylaxis and treatment of peripheral arterial embolism; and use as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; contraindications, doses, interactions, pregnancy and paediatric use and other warnings were not read. Labels differ between sponsors and change over time, and openFDA lists many heparin labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for Heparin Sodium Injection, Fresenius Kabi USA, LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5 (manufacturer Fresenius Kabi USA, LLC, application NDA017029), returned on 2026-11-09. The label text is dated 2026-04-30 (effective\_time). The openFDA search for heparin sodium labels under a new drug application returned 22 records from several sponsors and repackagers (for example Pfizer NDA201370, Hospira NDA018916, Baxter premixed bags); they were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%222a173253-dfdc-4d9d-8dee-b9c13e6fa9f5%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE (highlights). Retrieved 2026-11-09T13:16:11Z. Source state: Current. Version fingerprint: ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for Heparin Sodium Injection, Fresenius Kabi USA, LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5 (manufacturer Fresenius Kabi USA, LLC, application NDA017029), returned on 2026-11-09. The label text is dated 2026-04-30 (effective\_time). The openFDA search for heparin sodium labels under a new drug application returned 22 records from several sponsors and repackagers (for example Pfizer NDA201370, Hospira NDA018916, Baxter premixed bags); they were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%222a173253-dfdc-4d9d-8dee-b9c13e6fa9f5%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE, first bullet. Retrieved 2026-11-09T13:16:11Z. Source state: Current. Version fingerprint: ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777.
     How it applies: Label passage quoted in the research quote table (LB-05).
  3. Supports: openFDA drug label record for Heparin Sodium Injection, Fresenius Kabi USA, LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5 (manufacturer Fresenius Kabi USA, LLC, application NDA017029), returned on 2026-11-09. The label text is dated 2026-04-30 (effective\_time). The openFDA search for heparin sodium labels under a new drug application returned 22 records from several sponsors and repackagers (for example Pfizer NDA201370, Hospira NDA018916, Baxter premixed bags); they were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%222a173253-dfdc-4d9d-8dee-b9c13e6fa9f5%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE, second bullet. Retrieved 2026-11-09T13:16:11Z. Source state: Current. Version fingerprint: ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777.
     How it applies: Label passage quoted in the research quote table (LB-06).
  4. Supports: openFDA drug label record for Heparin Sodium Injection, Fresenius Kabi USA, LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5 (manufacturer Fresenius Kabi USA, LLC, application NDA017029), returned on 2026-11-09. The label text is dated 2026-04-30 (effective\_time). The openFDA search for heparin sodium labels under a new drug application returned 22 records from several sponsors and repackagers (for example Pfizer NDA201370, Hospira NDA018916, Baxter premixed bags); they were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%222a173253-dfdc-4d9d-8dee-b9c13e6fa9f5%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE, third bullet. Retrieved 2026-11-09T13:16:11Z. Source state: Current. Version fingerprint: ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777.
     How it applies: Label passage quoted in the research quote table (LB-07).
  5. Supports: openFDA drug label record for Heparin Sodium Injection, Fresenius Kabi USA, LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5 (manufacturer Fresenius Kabi USA, LLC, application NDA017029), returned on 2026-11-09. The label text is dated 2026-04-30 (effective\_time). The openFDA search for heparin sodium labels under a new drug application returned 22 records from several sponsors and repackagers (for example Pfizer NDA201370, Hospira NDA018916, Baxter premixed bags); they were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%222a173253-dfdc-4d9d-8dee-b9c13e6fa9f5%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE, fourth bullet. Retrieved 2026-11-09T13:16:11Z. Source state: Current. Version fingerprint: ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777.
     How it applies: Label passage quoted in the research quote table (LB-08).
  6. Supports: openFDA drug label record for Heparin Sodium Injection, Fresenius Kabi USA, LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5 (manufacturer Fresenius Kabi USA, LLC, application NDA017029), returned on 2026-11-09. The label text is dated 2026-04-30 (effective\_time). The openFDA search for heparin sodium labels under a new drug application returned 22 records from several sponsors and repackagers (for example Pfizer NDA201370, Hospira NDA018916, Baxter premixed bags); they were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%222a173253-dfdc-4d9d-8dee-b9c13e6fa9f5%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE, fifth bullet. Retrieved 2026-11-09T13:16:11Z. Source state: Current. Version fingerprint: ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777.
     How it applies: Label passage quoted in the research quote table (LB-09).
  7. Supports: openFDA drug label record for Heparin Sodium Injection, Fresenius Kabi USA, LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5 (manufacturer Fresenius Kabi USA, LLC, application NDA017029), returned on 2026-11-09. The label text is dated 2026-04-30 (effective\_time). The openFDA search for heparin sodium labels under a new drug application returned 22 records from several sponsors and repackagers (for example Pfizer NDA201370, Hospira NDA018916, Baxter premixed bags); they were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%222a173253-dfdc-4d9d-8dee-b9c13e6fa9f5%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE, sixth bullet. Retrieved 2026-11-09T13:16:11Z. Source state: Current. Version fingerprint: ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777.
     How it applies: Label passage quoted in the research quote table (LB-10).
  8. Supports: openFDA drug label record for Heparin Sodium Injection, Fresenius Kabi USA, LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5 (manufacturer Fresenius Kabi USA, LLC, application NDA017029), returned on 2026-11-09. The label text is dated 2026-04-30 (effective\_time). The openFDA search for heparin sodium labels under a new drug application returned 22 records from several sponsors and repackagers (for example Pfizer NDA201370, Hospira NDA018916, Baxter premixed bags); they were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%222a173253-dfdc-4d9d-8dee-b9c13e6fa9f5%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE, seventh bullet. Retrieved 2026-11-09T13:16:11Z. Source state: Current. Version fingerprint: ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777.
     How it applies: Label passage quoted in the research quote table (LB-11).
  9. Background: openFDA drug label record for Heparin Sodium Injection, Fresenius Kabi USA, LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5 (manufacturer Fresenius Kabi USA, LLC, application NDA017029), returned on 2026-11-09. The label text is dated 2026-04-30 (effective\_time). The openFDA search for heparin sodium labels under a new drug application returned 22 records from several sponsors and repackagers (for example Pfizer NDA201370, Hospira NDA018916, Baxter premixed bags); they were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%222a173253-dfdc-4d9d-8dee-b9c13e6fa9f5%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:16:11Z. Source state: Current. Version fingerprint: ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777.
     How it applies: Effective date of the label text read, 20260430.

## Connected pages

- Heparin is unfractionated heparin (FDA established pharmacologic class in RxClass): Heparins and low-molecular-weight heparins (`cardio:heparins-and-low-molecular-weight-heparins`)
- FDA label lists prophylaxis and treatment of venous thrombosis and pulmonary embolism as an indication: Pulmonary embolism (`cardio:pulmonary-embolism`) [a claim, not a settled fact; see claim `cardio:claim-fda-heparin-label-indications` and its context]
- FDA label lists prevention of postoperative deep venous thrombosis as an indication: Deep vein thrombosis (`cardio:deep-vein-thrombosis`) [a claim, not a settled fact; see claim `cardio:claim-fda-heparin-label-indications` and its context]
- FDA label lists atrial fibrillation with embolization as an indication: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`) [a claim, not a settled fact; see claim `cardio:claim-fda-heparin-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)
- Related to: Cerebral venous sinus thrombosis (`cardio:cerebral-venous-sinus-thrombosis`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 26 registry products
- 16 registry trials

## Provenance

Content hash: 1691b3b306aac939c3410424876ab8fcac0345d808c7731132b1b353e951dcc9
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
